Knights of Columbus Asset Advisors LLC Boosts Stake in Denali Therapeutics Inc. (NASDAQ:DNLI)

Knights of Columbus Asset Advisors LLC lifted its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) by 102.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 77,352 shares of the company’s stock after purchasing an additional 39,224 shares during the quarter. Knights of Columbus Asset Advisors LLC owned 0.06% of Denali Therapeutics worth $1,660,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of the business. Creative Planning raised its stake in shares of Denali Therapeutics by 4.4% in the second quarter. Creative Planning now owns 7,075 shares of the company’s stock worth $208,000 after purchasing an additional 295 shares during the last quarter. Rhumbline Advisers raised its stake in shares of Denali Therapeutics by 0.5% in the first quarter. Rhumbline Advisers now owns 97,145 shares of the company’s stock worth $3,125,000 after purchasing an additional 496 shares during the last quarter. PNC Financial Services Group Inc. increased its position in Denali Therapeutics by 35.4% during the second quarter. PNC Financial Services Group Inc. now owns 1,971 shares of the company’s stock valued at $58,000 after acquiring an additional 515 shares during the last quarter. Envestnet Asset Management Inc. increased its position in Denali Therapeutics by 1.3% during the first quarter. Envestnet Asset Management Inc. now owns 41,437 shares of the company’s stock valued at $955,000 after acquiring an additional 520 shares during the last quarter. Finally, E Fund Management Co. Ltd. increased its position in Denali Therapeutics by 4.3% during the fourth quarter. E Fund Management Co. Ltd. now owns 14,861 shares of the company’s stock valued at $413,000 after acquiring an additional 607 shares during the last quarter. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Insider Buying and Selling

In related news, Director Vicki L. Sato sold 1,666 shares of the business’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $18.29, for a total value of $30,471.14. Following the sale, the director now directly owns 118,043 shares in the company, valued at $2,159,006.47. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, Director Vicki L. Sato sold 1,666 shares of the business’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $18.29, for a total value of $30,471.14. Following the sale, the director now directly owns 118,043 shares in the company, valued at $2,159,006.47. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Steve E. Krognes sold 92,500 shares of the business’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $20.50, for a total value of $1,896,250.00. Following the completion of the sale, the director now owns 47,341 shares in the company, valued at $970,490.50. The disclosure for this sale can be found here. Over the last three months, insiders have sold 110,955 shares of company stock worth $2,218,802. Corporate insiders own 7.90% of the company’s stock.

Denali Therapeutics Price Performance

NASDAQ:DNLI opened at $16.00 on Friday. The stock has a 50-day simple moving average of $19.22 and a two-hundred day simple moving average of $19.22. Denali Therapeutics Inc. has a 52-week low of $15.45 and a 52-week high of $33.31.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings data on Tuesday, February 27th. The company reported ($0.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.81) by ($0.05). Denali Therapeutics had a negative return on equity of 13.50% and a negative net margin of 36.51%. During the same period in the prior year, the business posted ($0.75) earnings per share. As a group, equities analysts predict that Denali Therapeutics Inc. will post -2.62 earnings per share for the current year.

Analyst Upgrades and Downgrades

DNLI has been the subject of a number of research reports. Wedbush reiterated an “outperform” rating and set a $31.00 price objective on shares of Denali Therapeutics in a research report on Wednesday, February 28th. UBS Group reduced their price objective on Denali Therapeutics from $70.00 to $32.00 and set a “buy” rating for the company in a research report on Tuesday, April 9th. HC Wainwright reduced their price objective on Denali Therapeutics from $105.00 to $95.00 and set a “buy” rating for the company in a research report on Wednesday, February 28th. Finally, The Goldman Sachs Group reduced their price objective on Denali Therapeutics from $73.00 to $50.00 and set a “buy” rating for the company in a research report on Thursday, February 29th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $41.22.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.